logo
Analysis: Trump's cynical bait-and-switch on IVF

Analysis: Trump's cynical bait-and-switch on IVF

CNN17 hours ago
To hear President Donald Trump tell it, he wields an almost magical ability to lower Americans' health care costs. Yet that doesn't seem to extend to one area where he made explicit 2024 campaign promises: in vitro fertilization.
Just this weekend, Trump claimed he had lowered prescription drug costs as much as 1,500%. 'I don't mean 50%,' Trump clarified. 'I mean 14, 1,500%.'
This is obviously false and innumerate. You can't cut something more than 100%. It would mean drug companies were not only giving their drugs away for free, but actually paying people exorbitant sums to take them.
But the self-proclaimed 'father of IVF' appears to be an absentee dad.
His past vows to make the expensive and arduous IVF process 'free,' or at least require insurers to cover it, would fall under that seemingly magical umbrella as well, of course. But contrasting with his repeated pressure on drugmakers to lower costs — regardless of whether it's in his power to do so — Trump and his administration haven't done much of anything to make his IVF promises a reality. And it sounds like they've given up trying, to the extent they meant to pursue this policy in the first place.
Indeed, this looked a whole lot like a cynical pander during the 2024 campaign. And the administration's actions since then only seem to confirm it.
The Washington Post reported this weekend that the Trump administration has no actual plan to get insurers to cover IVF, more than six months into the new administration. The only concrete action Trump has taken on this front was back in February, when Trump instructed his domestic policy council to submit 'recommendations' on 'aggressively reducing out-of-pocket and health plan costs for IVF treatment.' He gave it 90 days.
Those recommendations were due in mid-May. But there is still no word on what, if any, recommendations were produced, and the administration last week reportedly declined to comment on the situation.
Fast forward to today, and the White House is apparently waving the white flag on Trump's biggest IVF promise. White House officials reportedly blamed inaction on the fact that Trump can't legally do this on his own and would need Congress to pass a law.
But that's not exactly the kind of impediment that Trump usually respects. His first six-plus months back in the presidency are rife with attempts to take bold and legally dubious executive actions that challenge the courts to stop him and companies to defy him. That's even applied to health care specifically.
Just last week, Trump sent letters to 17 major pharmaceutical company CEOs giving them 60 days to comply with an executive order that sought to lower prescription drug prices — even as experts say he has no such authority.
Trump has also sought to squeeze drugmakers in other ways, including threatening tariffs on pharmaceutical imports.
But the White House hasn't engaged in those hardball tactics to make insurers cover IVF. Administration officials aren't putting any public pressure on Congress to pass the law it says it needs, either, and they don't even seem to want to talk about the situation.
And if that's the new reality, it was entirely predictable — and predicted.
It was almost exactly a year ago when Trump debuted this promise.
'The government is going to pay for [IVF], or we're going to get — we'll mandate your insurance company to pay for it, which is going to be great. We're going to do that,' Trump said in August 2024. 'We want to produce babies in this country, right?'
That's not a 'we'll try to make this happen' promise. That's a 'we're going to make this happen' promise.
By October, Trump had declared himself the 'father of IVF' (something his campaign later labeled a joke). And Vice President JD Vance at his 2024 debate declared that making IVF more 'accessible' was core to the GOP's health agenda.
Even at the time, though, many dismissed the promises as hot air. Trump and his campaign were dealing with political fallout from strict red-state abortion bans, some of which had imperiled IVF access and coverage. Rhetorically bear-hugging IVF, a practice that's widely popular with voters, made sense.
But free IVF or ubiquitous insurance coverage never seemed an especially serious idea. Not only are IVF costs very expensive, stretching into tens of thousands of dollars per treatment, but many anti-abortion conservatives are starkly opposed to it. The process involves producing embryos that are never used and are often destroyed, creating a moral quandary for anti-abortion blocs that believe life begins at conception.
The idea that a Republican administration would spearhead making that cheaper — or even making the government pay for the creation of later-discarded embryos — was always far-fetched.
Because of all of this, many Republican lawmakers strongly rejected Trump's proposal when he debuted it. Some even acknowledged that it appeared to be a rather transparent bit of pandering that was not to be taken seriously.
'People get emotional about an issue, so they decide to completely pander and go way over a position they never really supported because they're afraid people accuse them,' Conservative Sen. Rand Paul of Kentucky said at the time.
It appears that's precisely what happened here.
That's bad news for anybody who might have been counting on this proposal. These issues, after all, deal with one of the most heart-wrenching circumstances that many families will ever confront: problems conceiving children. The cost is prohibitive for many people.
An October Ipsos poll also showed many Americans supported the idea. They said by a 55-26% margin that Congress should pass a law requiring insurers to cover IVF.
The Washington Post back in February profiled a young woman who had heard Trump deliver the promise and reluctantly voted for him. When the White House in February announced its limited IVF recommendations, saying it was delivering on Trump's promises, she called it 'bullsh*t.'
It's getting more and more difficult to quibble with that summary.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Cuts Deal With Rupert Murdoch Related To WSJ Lawsuit Over Epstein Story
Trump Cuts Deal With Rupert Murdoch Related To WSJ Lawsuit Over Epstein Story

Yahoo

time15 minutes ago

  • Yahoo

Trump Cuts Deal With Rupert Murdoch Related To WSJ Lawsuit Over Epstein Story

Donald Trump and Wall Street Journal owner Rupert Murdoch on Monday struck a deal related to the president's lawsuit against the paper over its publication of a story detailing a 'bawdy' birthday message Trump allegedly wrote to sex offender Jeffrey Epstein in 2003. While Trump had initially sought to have Murdoch deposed swiftly, citing, in part, his advanced age and long-standing health issues, the president has now agreed to remove that request, according to a Monday court filing first reported by Politico's Josh Gerstein. Trump sued Murdoch, the Journal's publisher and the reporters who authored an article the newspaper published last month reporting that the president wrote a lewd message to Epstein as part of an album British socialite Ghislaine Maxwell compiled for the disgraced financier's 50th birthday in 2003. Epstein died in jail in 2019 while awaiting trial on sex trafficking charges. Trump has denied writing the letter, attacking the newspaper for publishing its story and taking legal action over the report. Monday's agreement stipulates that until the 'Defendants' Motion to Dismiss the Complaint is adjudicated, the Parties agree not to engage in discovery.' The filing, though, notes that if the defendants' motion fails, Murdoch shall be deposed in person within 30 days of that decision. The document states that Murdoch has three days from when the court approves the agreement to provide Trump with a sworn declaration describing his current health status. 'Defendant Murdoch has further agreed to provide regularly scheduled updates to [Trump] regarding his health, including a mechanism for him to alert [Trump] if there is a material change in his health,' the document states. 'Failure to provide updates in the agreed-upon manner as set forth in the Abatement Agreement shall result in an expedited deposition of Defendant Murdoch.' Trump last week told reporters Murdoch wanted to settle the case. 'They are talking to us about doing something but we'll see what happens,' Trump said. 'Maybe they would like us to drop that, so we'll see ... yeah, they're having, they want to settle it.' 'When I get treated unfairly, I do things about it,' he added. Related... Trump Wants Murdoch Swiftly Deposed Over Epstein Story Because Of Age And Health Trump Sues WSJ Reporters, Murdoch For Libel After Epstein Birthday Card Story Trump Lashes Out At Rupert Murdoch Over WSJ Epstein Bombshell

Ultimate Pet Nutrition Launches Mobility Renew, A Breakthrough Joint Support Formula for Dogs
Ultimate Pet Nutrition Launches Mobility Renew, A Breakthrough Joint Support Formula for Dogs

Yahoo

time15 minutes ago

  • Yahoo

Ultimate Pet Nutrition Launches Mobility Renew, A Breakthrough Joint Support Formula for Dogs

A Veterinarian-Formulated Soft Chew Joint Support Supplement Designed to Promote Flexibility, Soothe Stiffness, and Support Long-Term Mobility in Dogs LOS ANGELES, Aug. 5, 2025 /PRNewswire/ -- Ultimate Pet Nutrition® proudly announces the launch of Mobility Renew™, a veterinarian-developed soft chew supplement designed to support canine joint health, flexibility, and comfort. Crafted by renowned veterinarian Dr. Gary Richter, this premium formula combines clinically-studied ingredients to help dogs of all ages maintain active, comfortable lives.* "What looks like 'slowing down' is often discomfort," explains Dr. Richter. "I developed Mobility Renew to help improve their comfort and activity. A lot of research shows UCII collagen is more effective than glucosamine for joint support. Combined with hyaluronic acid, omega-3s, eggshell membrane, boswellia, and ashwagandha, I believe Mobility Renew is the most powerful joint supplement for dogs on the market."* Mobility Renew is a step above the conventional joint support supplements we have been using for the past twenty years. All this time, we have been largely relying on glucosamine and chondroitin for joints. While these compounds have their benefits, the UC-II collagen in Mobility Renew is much more effective, providing joint and cartilage support and comfort than the ingredients in yesterday's supplements. While the UC-II collagen alone can provide effective relief, the addition of joint support, antioxidants, and omega-3 fats helps promote a healthy joint environment in ways that the older supplements can't. The ingredients in Mobility Renew could be the future of supporting and maintaining optimal joint health in our pets.* What is Ultimate Pet Nutrition Mobility Renew?Ultimate Pet Nutrition Mobility Renew is an advanced hip and joint supplement formulated to support healthy joint function, reduce stiffness, and support cartilage and connective tissue in dogs. This daily soft chew is ideal for aging dogs, active breeds, or any pup experiencing occasional joint discomfort due to normal activity.* Featuring a synergistic blend of premium ingredients—including UC-II® Collagen, MSM, Eggshell Membrane, Salmon Oil, Hyaluronic Acid, and Boswellia—Mobility Renew™ offers comprehensive support for joint mobility and comfort. Each soft chew is designed to help ease joint stiffness, support cartilage development, and maintain healthy bone and joint function.* What sets Ultimate Pet Nutrition Mobility Renew apart from other dog joint supplements is its focus on clinically backed ingredients that can help improve mobility and flexibility. It's an ideal choice for pet parents seeking a natural, holistic approach to joint care. Plus, it's easy-to-administer soft chew format makes it simple to add to your dog's daily routine (as in, no need to hide in peanut butter to get them to eat it!).* Key Ingredients in Ultimate Pet Nutrition Mobility Renew UC-II® Collagen: A patented form of undenatured type II collagen that supports joint comfort, flexibility, and healthy joint function by targeting the root causes of stiffness. * Methylsulfonylmethane (MSM): A naturally occurring compound that supports joint health by promoting normal recovery after exercise. * Eggshell Membrane: Rich in naturally occurring compounds like collagen, elastin, and glycosaminoglycans, which are crucial for top-notch joint health.* Salmon Oil: Packed with omega-3 fatty acids, which have been shown to support healthy joint mobility and reduce occasional discomfort in dogs.* Hyaluronic Acid: A naturally occurring compound that acts as a lubricant for the joints, helping to support the joints during activity.* Boswellia: A natural herb that supports smooth, comfortable joint movement, especially after exercise or during periods of increased activity.* Ultimate Pet Nutrition Mobility Renew FAQ How do I use Ultimate Pet Nutrition Mobility Renew? To use Ultimate Pet Nutrition Mobility Renew, give the appropriate number of soft chews to your dog once per day based on the chart. Where can I purchase Ultimate Pet Nutrition Mobility Renew? Ultimate Pet Nutrition Mobility Renew can be purchased on for $49.95. About Ultimate Pet NutritionFounded by Dr. Gary Richter, Ultimate Pet Nutrition believes optimal nutrition is the key to a happy life. It's our mission to support your pet's health with premium quality food, treats, and supplements developed by Dr. Richter himself—because we understand your pet is like family, and they deserve only the best. In 2025, Dr. Richter teamed up with award-winning actor Rob Lowe, a dog dad himself and one of the most renowned actors and health advocates in the world, to spread the word about good nutrition and form a community that helps your pet live a happier, healthier life. Best-selling products include our popular freeze-dried raw dog food, Nutra Complete for Dog, and the popular freeze-dried raw treats, Nutra Bites. Ultimate Pet Nutrition products are also available on Amazon. Follow Ultimate Pet Nutrition on Instagram @ultimatepetnutrition and YouTube @ultimatepetnutrition. For retail opportunities, contact retail@ About Dr. Gary RichterDr. Gary Richter is a leader in integrating advanced Western medicine and Eastern holistic practices to provide comprehensive care for pets. As the founder of Ultimate Pet Nutrition, his unwavering dedication and passion for animals have earned him and his animal hospitals over 30 prestigious awards, including "Best Veterinarian" and "Best Alternative Medicine Provider." Dr. Richter is also the international best-selling author of The Ultimate Pet Health Guide and his latest books, Longevity for Cats and Longevity for Dogs, offering pet owners 'biohacking for pets" insight to help their pets live healthier, happier lives. To learn more, visit or follow him on Instagram @petvetexpert. *All pets are unique. Your results can and will vary. Press Contact:Laura Baumgartner - Asylum PRlbaumgartner@ View original content to download multimedia: SOURCE Ultimate Pet Nutrition Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board

Yahoo

time15 minutes ago

  • Yahoo

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board

SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology. "I am deeply impressed with Iambic's team, its platform and application of AI and machine learning to address some of the most complex challenges in cancer and drug discovery," said Dr. Deshaies. "Iambic has differentiated itself by using its technology to uncover truly differentiated oncology candidates and rapidly advancing them into the clinic. I look forward to supporting the team's breakthrough science as they work to bring new therapies to patients." Prior to Amgen, Dr. Deshaies was a professor of biology at Caltech and an investigator at the Howard Hughes Medical Institute. His research focused on mechanisms and regulation of protein homeostasis in eukaryotic cells, with a particular focus on the ubiquitin-proteasome system and the degradation of proteins – work that provided the biochemical foundation for his lab's discovery of proteolysis-targeting chimeras (PROTACS) as a new class of candidate therapeutics. He also co-founded the biotechnology companies Proteolix and Cleave Biosciences and is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. "We are thrilled to have Ray join our SAB and look forward to collaborating with him as we shape our pipeline of clinical programs and broaden the potential of our platform to unlock new targets for a range of critical disease areas," said Tom Miller, PhD, Iambic's co-founder and CEO. "Ray's achievements as a scientist, an innovator and a builder of world-class research organizations, make him an ideal partner as we continue to scale and define opportunities enabled by our AI-driven discovery engine." About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store